Article info
PDFResearch
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
- Correspondence to Dr Aaron S Kesselheim, Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA; akesselheim{at}bwh.harvard.edu
Citation
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
Publication history
- Received April 14, 2022
- Accepted November 21, 2022
- First published December 12, 2022.
Online issue publication
December 12, 2022
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.